[Efficacy of different doses of botox in treatment of chronic migraine].

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Zhurnal Nevrologii i Psikhiatrii imeni S.S. Korsakova

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.17116/jnevro20171178144-48PMID 28884716
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Редкие типы первичной головной боли

  2019cited by this paper
• [Strategies on the improvement of chronic migraine treatment efficacy].

  2015cited by this paper
• Adherence to oral migraine-preventive medications among patients with chronic migraine

  2015cited by this paper
• Selective inhibition of meningeal nociceptors by botulinum neurotoxin type A: Therapeutic implications for migraine and other pains

  2014cited by this paper
• Therapeutic use of botulinum toxin in migraine: mechanisms of action

  2014cited by this paper
• Per cent of patients with chronic migraine who responded per onabotulinumtoxinA treatment cycle: PREEMPT

  2014cited by this paper
• The International Classification of Headache Disorders, 3rd edition (beta version)

  2013cited by this paper
• OnabotulinumtoxinA for chronic migraine: efficacy, safety, and tolerability in patients who received all five treatment cycles in the PREEMPT clinical program

  2013cited by this paper
• The prevalence of primary headache disorders in Russia: A countrywide survey

  2012cited by this paper
• Updates on the antinociceptive mechanism hypothesis of botulinum toxin A.

  2011cited by this paper
• Dose‐ and volume dependent‐response to intramuscular injection of botulinum neurotoxin‐A optimizes muscle force decrement in mice

  2011cited by this paper
• Global prevalence of chronic migraine: A systematic review

  2010cited by this paper
• OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

  2010cited by this paper
• Sensory innervation of the calvarial bones of the mouse

  2009cited by this paper
• Influence of disease features on adherence to prophylactic migraine medication

  2008cited by this paper
• Treatment of Depression with Botulinum Toxin A: A Case Series

  2006cited by this paper
• The effect of intranasal injection of botulinum toxin A on the symptoms of vasomotor rhinitis.

  2006cited by this paper
• Central Sensitization Theory of Migraine: Clinical Implications

  2006cited by this paper
• Botulinum toxin type A for the prophylactic treatment of chronic daily headache: a randomized, double-blind, placebo-controlled trial.

  2005cited by this paper
• Botulinum Toxin Type A (BOTOX®) for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double‐Blind, Placebo‐Controlled Trial

  2005cited by this paper
• Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study

  2005cited by this paper
• A Randomized Double-blind Placebo-controlled Trial

  2004cited by this paper
• Migraine--current understanding and treatment.

  2002cited by this paper
• Botulinum toxin type A (BOTOX) for treatment of migraine.

  2001cited by this paper
• Botulinum Toxin Type A as a Migraine Preventive Treatment

  2000cited by this paper
• Botulinum toxin type A as a migraine preventive treatment. For the BOTOX Migraine Clinical Research Group.

  2000cited by this paper
• Botulinum toxin type A (BOTOX) for treatment of migraine headaches: An open-label study

  2000cited by this paper
• Factors influencing success and dose-effect relation of botulinum a treatment

  1996cited by this paper
• Tension Headache: Botulinum Toxin Paralysis of Temporal Muscles

  1994cited by this paper
• Tension

  1878cited by this paper

• OnabotulinumtoxinA in chronic migraine: is the response dose dependent?

  2022cites this paper
• [Real-world migraine burden: clinical and economic aspects].

  2019cites this paper
• The organizations of specialized medical care for patients with headache

  2019cites this paper
• The Burden of Migraine in Real Clinical Practice: Clinical and Economic Aspects

  2019cites this paper
• The Burden of Migraine in Real Clinical Practice: Clinical and Economic Aspects

  2019cites this paper